Bill would expand drug price negotiations and cap out-of-pocket costs at $2,000

What does this do?

HR 6166 would raise the number of drugs Medicare can negotiate annually from 20 to 50, require negotiators to consider prices paid in countries like Canada, France, and the United Kingdom, and extend negotiated prices to people with private insurance. Starting in 2027, out-of-pocket prescription drug costs for people with private insurance would be capped at $2,000 per person per year, with insulin capped at $35 per month and no deductible allowed for insulin. The bill would also apply inflation rebate penalties, currently limited to Medicare, to drugs sold in the private insurance market.

Who does it affect?

People with private health insurance through employers or the individual market, Medicare patients, and people with diabetes who rely on insulin would be directly affected. Drug manufacturers and insurance companies would face new rules under this legislation, and employers who provide health coverage would also see changes.

Why does it matter?

Extending inflation rebates to the commercial market creates a financial penalty for drug companies that raise prices faster than inflation outside of Medicare. Private insurers have the option to opt out of applying negotiated Medicare drug prices to their plans, which may limit how broadly the negotiated prices take effect.

What does it cost, and who pays?

• Insulin capped at $35/month, private plans
• Rebates owed when prices beat inflation
• $2,000 annual out-of-pocket cap, 2027

Where does it stand?